TrialInternational journal of hematology2023

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.

Daisuke Minakata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.